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Abstract Phosphoinositides are signalling lipids that are
crucial for major signalling events as well as established
regulators of membrane trafficking. Control of endosomal
sorting and endosomal homeostasis requires phosphatidyli-
nositol-3-phosphate (PI(3)P) and phosphatidylinositol-3,5-
bisphosphate (PI(3,5)P2), the latter a lipid of low abundance
but significant physiological relevance. PI(3,5)P2 is formed
by phosphorylation of PI(3)P by the PIKfyve complexwhich
is crucial for maintaining endosomal homeostasis. Interest-
ingly, loss of PIKfyve function results in dramatic
neurodegeneration. Despite the significance of PIKfyve, its
regulation is still poorly understood. Here we show that the
Amyloid Precursor Protein (APP), a central molecule in
Alzheimer’s disease, associates with the PIKfyve complex
(consisting of Vac14, PIKfyve and Fig4) and that the APP
intracellular domain directly binds purified Vac14. We also
show that the closely related APP paralogues, APLP1 and 2
associate with the PIKfyve complex. Whether APP family
proteins can additionally form direct protein–protein inter-
action with PIKfyve or Fig4 remains to be explored. We
show that APP binding to the PIKfyve complex drives for-
mation of PI(3,5)P2 positive vesicles and that APP gene
family members are required for supporting PIKfyve func-
tion. Interestingly, the PIKfyve complex is required for APP
trafficking, suggesting a feedback loop in which APP, by
binding to and stimulating PI(3,5)P2 vesicle formation may
control its own trafficking. These data suggest that altered
APP processing, as observed in Alzheimer’s disease, may
disrupt PI(3,5)P2 metabolism, endosomal sorting and
homeostasis with important implications for our under-
standing of the mechanism of neurodegeneration in
Alzheimer’s disease.
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Abbreviations
AICD Amyloid precursor protein intracellular
domain
APP Amyloid precursor proteins
APPDAICD APP lacking its intracellular domain
BACE1 Beta secretase
BSA Bovine serum albumin
PBS Phosphate buffered saline
MBP Maltose binding protein
PI(3)P Phosphatidylinositol-3-phosphate
PI(3,5)P2 Phosphatidylinositol-3,5-bisphosphate
TGN Trans-Golgi-network
Introduction
In eukaryotes, the endosomal system plays a pivotal role
for the sorting of endocytosed molecules and establishing
which are to be reused and which ones are committed to
destruction. The organisation of the endosomal system
reflects this purpose. Endocytosed material is sorted in
early endosomes for either recycling to the plasma mem-
brane or retrograde transport to the trans-Golgi-network
(TGN) (reviewed in [1]). As endosomes mature they
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acquire an increasing number of intraluminal vesicles into
which cargoes destined for lysosomal degradation are
sorted [2]. Ultimately, late endosomes undergo fusion with
lysosomes, leading to the proteolytic degradation of
transmembrane proteins contained within intraluminal
vesicles as well as soluble protein contained in the fluid
phase late endosomes.
Endosomal sorting is crucially underpinned by phos-
phoinositides. The signature lipid of the endosomal system
is phosphatidylinositol-3-phosphate (PI(3)P) which is able
to recruit a large number of PI(3)P binding proteins onto
endosomes [3]. Binding of PI(3)P is enabled by a number
of binding domains, well-characterised examples are PX-
and FYVE-domains [4–6]. The significance of PI(3)P is
apparent when its formation is inhibited by Wortmannin
which disrupts numerous endosomal sorting processes [7].
Another endosomal phosphoinositide, PI(3,5)P2, has
been far less studied, certainly in part because inhibitors of
its formation have only recently become available. Fur-
thermore, it is one of the least abundant phosphoinositides,
considerably complicating its biochemical detection.
PI(3,5)P2 is produced by phosphorylation of PI(3)P at the
5-position by the PIKfyve complex [8–10]. The PIKfyve
complex consists in mammals of three subunits, PIKfvye
(also known as Fab1), Vac14 (ArPIKfyve) and Fig4 (Sac3)
[9]. The PIKfyve subunit contains the kinase domain,
Vac14 acts as a scaffold for the complex, while Fig4 has an
interesting dual role as a necessary activator of PIKfyve but
can also function as a PI(3,5)P2 specific 5-phosphatase [8,
9, 11–13]. Recently it has been shown that the PIKfyve
complex is the only source in mammalian cells for pro-
ducing PI(3,5)P2 [14].
The most prominent and best established phenotype of
PIKfyve dysfunction is the accumulation of aberrant vac-
uoles in the cytoplasm that stem from the endosomal
system [15, 16]. The occurrence of these vacuoles has been
established when a kinase-dead PIKfyve mutant was
expressed, by RNAi suppression of PIKfyve, genetic
ablation of PIKfyve complex members or pharmacological
inhibition [15–18]. In every instance pronounced vacuo-
lation indicated PIKfyve dysfunction. PIKfyve suppression
also led to defective endosome-to-TGN transport of a
number of cargoes [16, 19, 20]. How does PIKfyve func-
tion lead to vacuole formation? It was shown that PI(3,5)P2
is able to bind to and activate the TRPML-1 channel (also
known as mucolipin 1). Inactivation of TRPML-1 repli-
cates the vacuolation phenotype observed upon loss of
PIKfyve, suggesting that the PIKfyve/TRPML-1 interplay
is crucial for endosomal homeostasis [19].
When analysing the consequences of PIKfyve dysfunc-
tion, there is striking evidence that PIKfyve function is
crucial for neuronal integrity [14, 17, 21]. In mouse models
loss of function of any of its subunits by mutation or
knock-out resulted in serious neurodegeneration and
lethality shortly after birth [14, 17, 21]. Mutations in Fig4
have also been shown to lead to Charcot–Marie–Tooth
syndrome and amyotrophic lateral sclerosis, both neu-
rodegenerative disorders [21, 22].
How PIKfyve complex activity is controlled in metazoa
currently remains entirely unclear. However, in a recent
study, we identified the Amyloid Precursor Protein (APP)
as a putative, novel interaction partner of the PIKfyve
complex (Balklava et al., in press), raising the possibility
that APP and the PIKfyve complex may have a shared
function.
APP is a molecule known to be of central importance in
Alzheimer’s disease, a progressive, neurodegenerative
disease that results in debilitating incapacity of patients and
is ultimately fatal. Alzheimer’s disease occurs in a sporadic
form (also described as late onset Alzheimer’s disease) of
unclear cause, while the familial form (known as early
onset) is caused by mutations either in the Amyloid Pre-
cursor Protein (APP) gene or the APP cleaving gamma-
secretase complex [23, 24].
A major step was the realisation that APP cleavage by
the gamma-secretase, if preceded by so-called beta-secre-
tase (BACE1) cleavage of APP results in a small,
aggregation-prone peptide known as beta amyloid. This
peptide can be found as a principle constituent of so-called
‘senile’ plaques that can be observed in patient brain sec-
tions. Both lines of evidence suggest that APP cleavage is a
central event in Alzheimer’s disease [25].
Extensive work has been carried out to better understand
APP processing by beta and gamma secretases and the
pathophysiological consequences of beta-amyloid produc-
tion. Much less effort has been dedicated to understanding
the physiological role of APP (reviewed in [26]). APP has
been shown to be enriched in synapses and is known to
control synaptic transmission and synapse formation.
However, the molecular mechanisms are not clear [26].
Further complicating the question concerning APP
function is that besides APP two closely related APP par-
alogues, APLP1 and APLP2, exist in mammals. While
APLP1 expression appears to be restricted to the brain,
APP and APLP2 are ubiquitously expressed. Genetic
analysis of the APP gene family strongly suggested that
there is a large functional overlap between the different
members of the APP gene family [27]. For example knock-
out mice deficient for either APP or APLP2 have very
subtle defects while double knock-out is peri-natally lethal
for the vast majority of animals [27].
APP as a single spanning transmembrane protein is
produced in the ER and traffics between the Golgi com-
plex, the plasma membrane and endosomes (reviewed in
[28]). Its trafficking has been studied in considerable detail.
APP is sorted in the TGN by Adaptor protein complex 4
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[29]. Endocytosis of APP is organised by AP-2, while
endosomal sorting of APP is mediated by the retromer
complex [30, 31] which enables endosome-to-TGN trans-
port, and, depending on subunit composition, recycling to
the plasma membrane [32–34].
Our recent work aimed to establish the interactome of
the intracellular domain of APP to elucidate its function.
Surprisingly, we found that all three subunits of the PIK-
fyve complex (e.g., PIKfyve, Vac14 and Fig4) associated
with the intracellular domain of APP (Balklava et al., in
press). When studying the interplay using C. elegans
genetics, it became clear that APP functionally interacts
with the PIKfyve complex, suggesting that APP and PIK-
fyve function in the same pathway. However, the
mechanism of this remained unclear.
Here we show that APP directly binds Vac14 of the
PIKfyve complex. We demonstrate that overexpression of
APP or its intracellular domain AICD stimulates the for-
mation of PI(3,5)P2 positive vesicles in a PIKfyve-
dependent manner. Conversely, RNAi mediated suppres-
sion of APP and APLP2 decreased the number of PI(3,5)P2
vesicles, suggesting that APP gene family members regu-
late endosomal sorting via PIKfyve. We also show that
suppression of APP gene family members increased inci-
dence of vacuoles and cellular susceptibility to vacuole
formation when PIKfyve function becomes compromised.
Finally, we show that PIKfyve activity is required for
successful sorting of APP at endosomal membranes,
establishing a complex and reciprocal relationship between
APP and PIKfyve with interesting implications for our
understanding of Alzheimer’s disease.
Materials and methods
Antibodies
APP beta-amyloid (sc-53822), LampI (sc-20011), Vac14
(sc-271831), PIKfyve (sc-100408) (all from Santa Cruz
Biotechnology). APLP2 (ab140624) (Abcam). EEA1
(610457) (BD Biosciences). MBP (2396S), Anti-mouse
IgG, HRP-linked (7076), Anti-rabbit IgG, HRP-linked
(7074), Anti-rabbit IgG Fab2 Alexa Four 555 (44135),
Anti-mouse IgG Fab2 Alexa Four 555 (44095) (All from
Cell Signalling Technology).
Plasmids
pEGFP-n1-APP was created by PCR amplification of
APP695 from cDNA extracted from HeLa cells and cloned
into pEGFP-n1 (Clontech), followed by subcloning into
pmCherry-n1 and pYFP-n1 using NheI and SalI. The
intracellular domain was removed by PCR amplification of
APP and cloning into pYFP-n1 using NheI and SalI. AICD
and the various AICD truncation mutations were PCR
amplified using pEGFP-n1-APP as template and cloned
into pEGFP-n1 or pYFP-n1. For bacterial expression the
various truncations were PCR amplified and cloned into a
pET28 derived plasmid described in [35] using BamHI and
XhoI. pEGFP-c3-2xML1N was kindly provided by Dr.
H. Xu (University of Michigan) [36] and was PCR cloned
into pmCherry-c1 using XhoI and BamHI. The expression
plasmid for production of His-tagged Vac14 was kindly
provided by Dr. L. Weisman (University of Michigan).
Expression plasmids for the APLP1 and 2 intracellular
domains as well as AICD mutations in the YENPTY motif
were synthesised by GeneArt (Life Technologies) with
codon-optimisation for E. coli and subcloned into pET28-
MBP-TEV using XhoI/BamHI for bacterial expression.
Proteo-liposome recruitments for analysing
the APP/PIKfyve complex interaction
Recombinant 6xHis MBP tagged cytoplasmic receptor tails
were expressed in E. coli (Bl21DE3) and purified as
described in [35, 37]. Recruitments were carried out as
described in [35, 37] with the following modification: The
proteo-liposomeswere separated from the cytosol or purified
Vac14 using a sucrose cushion (2 ml 60 % sucrose inRB and
8 ml 5 % sucrose in RB) in a Beckman coulter optima
L-100k ultracentrifuge (SW40 rotor) at 38,000 rpm for
90 min at 4 C. The interface between the two sucrose
phases containing the proteo-liposomeswas removed and re-
suspended in 11 ml of Recruitment Buffer (RB) and pelleted
in a Beckman coulter optima L-100k ultracentrifuge (SW40
rotor) at 38,000 rpm for 1 h at 4 C. The supernatant was
discarded and the pellet re-suspended in 100 ll of 29
Laemmli buffer. The samples were analysed by SDS-PAGE
and western blotting for interacting proteins.
Purification of recombinant Vac14
Recombinant, His-tagged Vac14 was expressed at 25 C
for approximately 18 h and purified using Ni-NTA (Pierce)
according to the manufacturers protocol.
Maltose binding protein pull-downs for testing
the interaction of recombinant Vac14 with AICD
20 lg of purified recombinant, MBP-AICD, MBP-Tr1,
MBP-Tr2, MBP-Tr3, MBP-Tr4 and MBP were incubated
with 10 lg of purified His-Vac14 for 1 h rocking on ice in
200 ll PD-buffer (25 mM HEPES pH 7.0, 50 mM KCl,
1 mM MgCl2) followed by incubation with 20 ll of amy-
lose resin beads (New England Biolabs) equilibrated in PD-
buffer. Samples were incubated rocking on ice for 1 h and
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the amylose beads spun down using centrifugation
(1000 rpm, 1 min) and washed 5 times using PD-buffer.
Proteins were eluted by incubating the beads with 50 ll of
PD-buffer containing 20 mM maltose for 10 min on ice,
followed by SDS-PAGE and western blotting.
Transfections
HeLa cells were seeded onto glass coverslips in a 24-well
plate at a density of 100,000 cells per well and incubated at
37 C with 5 % CO2 overnight. The following day the cells
were co-transfected with a combination of the plasmids
indicated using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. Cells were fixed and
mounted the following day or selected with G418 for the
isolation of a stably transfected population.
Fixed cell imaging and immunostaining
HeLa cells were fixed for 20 min in 4 % paraformaldehyde
depolymerised in PBS followed by twowashes in PBS. Cells
were permeabilised using 0.1 % Triton X-100 in PBS for
4 min followed by two washes in PBS and blocking using
2 %bovine serum albumin (BSA) in PBS for at least 15 min.
Cells were stained by use of a primary antibody (diluted in
2 % BSA, incubation for 1 h at RT) followed by three
washes in PBS and incubation with the secondary antibody
(diluted 1:500 in 2 % BSA, incubation for 1 h, RT. Finally,
cells were washed thrice using PBS and mounted using
Mowiol. Samples were imaged on an Leica SP5 TCS II MP
confocal microscope with a 639 oil immersion lense.
Quantification of APP-GFP localisation in relation
to EEA1, LampI and GM130
Image analysis was performed using ImageJ following [38]
for analysis of ciMPR localisation with the following mod-
ification: Briefly, EEA1, LampI or GM130 staining was used
to define a mask by applying a manual threshold, defining
organelles positive and negative for the respective marker.
Then the APP-GFP label inside the mask was measured as
well as the total cellular APP-GFP label, using the ‘ImageJ’s
‘Histogram’’ function. APP-GFP label inside the mask was
calculated as a percentage of total APP-GFP label.
Live cell imaging for the observation of APP-GFP and
mCherry-ML1Nx2 was carried out as describe in [39].
Quantification of ML1N positive vesicles
Images were imported into ImageJ and maximum projec-
tions created from the Z-stacks. Each cell to be quantified
was individually selected. mCherry ML1Nx2 positive
structures were analysed using the MosaicSuite for ImageJ
[40]. This allows automatic image segmentation, automatic
detection of structures such as labelled vesicles and quan-
tification of the number of detected objects as well as object
intensity and object shape [40]. The advantage of this
methodology is that the algorithm makes no assumptions
about the shape of the objects to be detected [40]. Further-
more, it does not require any manual initialisation of the
segmentation process, precluding the introduction of bias by
the observer. The following parameters were used: Back-
ground subtraction: 10. Regularisation: 0.1.Minimumobject
intensity: 0.3 (for overexpression experiments) and 0.15 (for
RNAi experiments). The average number of mCherry-
ML1Nx2 structures per cell was measured using the
MosaicSuite for each condition together with the average
intensity of these structures. Statistical significance of the
datawas analysed using a one-wayANOVA (a = 0.05)with
a Tukey’s post hoc test in GraphPad Prism 6.
RNAi suppression
HeLa cells were seeded at a density of 50,000 cells/well in
a 24 well plate. The following day, prior to transfection, the
medium was exchanged. The transfection mix containing
100 ll Optimem, 12 pmol of RNAi duplex and 3 ll of
Interferin (PolyPlus) was prepared, incubated for 20 min at
RT and added to cells, resulting in a final RNAi concen-
tration of 20 nM. Cells were fixed for imaging or lysed for
Western experiments 3 days after transfection.
Vacuole quantification
3 days post-RNAi transfection living cells were imaged
using a Nikon Eclipse TS100 microscope with a 409
objective. A minimum of 25 cells per image were scored
manually for the presence of vacuoles as previously
established [16].
PIKfyve inhibition using YM201636 and Apilimod
YM201636 was purchased from Abcam (ab141370).
Apilimod was purchased from USBiolgical (002800). Both
YM201636 and Apilimod were applied at the concentra-
tions and for the times indicated in the figure legends. It
was noted that the YM201636 PIKfyve inhibitor easily
precipitated in the presence of various transfection
reagents. Therefore, cells were washed at least three times
with complete medium before YM201636 was applied.
Statistical treatment
As in all experiments multiple samples were compared we
utilised one-way ANOVA (a = 0.05) tests in GraphPad
Prism 6 with Tukey’s or Dunett’s post hoc tests.
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Results
APP interacts with the Vac14 subunit of the PIKfyve
complex
Until recently the study of interaction partners of the
intracellular domain of transmembrane receptors, particu-
larly their association with coats and other trafficking
regulators has been exceedingly difficult. The major con-
tributing factor to this difficulty has been that coats and
their regulators rely on membrane attachment as well as the
binding to cytoplasmic domains of receptors [41]. In the
absence of a membrane context, it can be extremely diffi-
cult to detect the binding of coats to receptors.
This limitation has been overcome with the creation of
the proteo-liposome system, in which the cytoplasmic
domains of transmembrane proteins is covalently coupled to
preformed liposomes in a sterically defined manner [35, 37,
42]. This mimics the situation encountered in cells where the
cytoplasmic receptor domain is presented with a membrane
environment, allowing the efficient recruitment of coats and
their regulators [35, 42]. In our recent study we utilised this
powerful system for identifying novel interaction partners of
the APP intracellular domain (known as AICD) using mass
spectrometry (Balklava et al., in press).
Here, we utilised this system to study the interaction
between APP and the PIKfyve complex in detail. First we
created three C-terminal truncations and one N-terminal
deletion of the 47 amino acid long AICD and tested their
potential for binding the PIKfyve complex using proteo-
liposomes. Full length AICD and an N-terminal deletion
removing 10 amino acids (called AICD-Tr.4) are both
capable of binding both Vac14 and PIKfyve from pig brain
cytosol (Fig. 1a–d). In contrast, any C-terminal truncation
removing 37, 26 or 7 amino acids from AICD (AICD-Tr.1,
2 and 3, respectively), abolished binding of both Vac14 and
PIKfyve. To explore the nature of the binding site in more
detail, we turned our attention to the highly conserved
YENPTY motif next to the deletion introduced in AICD-
Tr.3. This motif is conserved in evolution from humans
down to very simple metazoans such as the cnidarian Ne-
matostella, arguing for an important and conserved
function of this motif. We created three ‘double point’
mutations, exchanging two amino acids in full length
AICD for two alanines, yielding the mutants: AICD-
AANPTY, AICD-YEAATY, and AICD-YENPAA. We
tested their binding capacity and found that any of the three
mutations either abolished or strongly reduced binding of
Vac14 and PIKfyve in proteo-liposome recruitments,
demonstrating that this motif in addition to sequence ele-
ments identified using AICD-Tr.3 are necessary for APP
binding of the PIKfyve complex (Fig. 1e–g). These data
suggested that the PIKfyve complex binding site is located
in close proximity to the C-terminus of AICD and spans the
conserved YENPTY motif.
Next we tested the binding capability of bacterially
expressed and purified Vac14 and found that it bound
AICD on proteo-liposomes (Fig. 1h, i). We also tested the
binding of purified Vac14 using classical pull-downs. We
found that both AICD and Tr.4 were able to bring down
Vac14, while Tr. 1–3 and the negative control MBP failed
to bind Vac14, fully recapitulating the results obtained
using proteo-liposome recruitments (Fig. 1j). These data
suggest that APP forms a direct protein–protein interaction
with the Vac14 subunit of the PIKfyve complex.
As the YENPTY sequence motif is also found in the
APP related genes, APLP1 and APLP2 (alignment shown
in Fig. 1k) we tested their ability to bind Vac14. We found
that both APLP1 and APLP2 were able to bind Vac14 and
PIKfyve (Fig. 1l–n), suggesting that all members of the
mammalian APP gene family are likely to be PIKfyve
complex interactors.
APP or AICD overexpression stimulates
the formation of ML1Nx2 positive vesicles
What is the functional significance of this interaction?
Most previous work has focused on the roles that APP or
the APP gene family may play in neurons. However, APP
and APLP2 are expressed ubiquitously, while APLP1
expression appears to be restricted to neurons [43]. This
clearly suggests that the APP gene family is likely to have
functions not limited to the brain. The PIKfyve complex is
also widely expressed [44]. To test for a generic APP
function we choose the epithelium derived HeLa cell line,
in which the function of PIKfyve has been thoroughly
characterised [16, 20].
First we asked whether overexpression of APP or APP’s
intracellular domain may alter production of PI(3,5)P2. To
test this, we utilised the recently established PI(3,5)P2
specific probe ML1Nx2 [36]. Fusion of a tandem repeat of
this lipid binding domain of the PI(3,5)P2 binder TRPML-1
to a fluorescent protein allows the detection of PI(3,5)P2 in
a spatially and temporally defined manner which had not
been previously possible [36]. This probe has also been
used successfully in a study that established that PIKfyve
function is required for AMPA receptor trafficking and
synaptic depression, further validating it as a tool for
analysing PI(3,5)P2 dynamics in vivo [45]. mCherry-
ML1Nx2 was transfected into cells and analysed by con-
focal microscopy. Structures labelled by ML1Nx2 were
analysed using the MosaicSuite segmentation tool of
ImageJ, allowing unbiased, automated detection of
ML1Nx2 positive structures and their intensity.
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Overexpression of APP-GFP led to a strong increase in
the number of ML1Nx2 positive vesicles per cell compared
to the expression of GFP as a negative control (Fig. 2a, c).
By contrast, overexpression of APP lacking the
intracellular domain (APPDAICD) did not significantly
alter the number of ML1Nx2 positive vesicles, suggesting
that the intracellular domain of APP is required for stim-
ulating the formation of ML1Nx2 positive vesicles
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(Fig. 2a, c). To confirm that the increase of ML1Nx2
positive vesicles upon overexpression of APP truly
depends on PIKfyve activity we combined APP overex-
pression with pharmacological PIKfyve inhibition using
YM201636 [18]. Upon PIKfyve inhibition the number of
ML1Nx2 vesicles was drastically reduced, demonstrating
that the APP-induced increase of ML1Nx2 positive vesi-
cles is indeed dependent on PIKfyve activity (Fig. 2b, c).
This is fully in line with the recent report of the Weisman
lab that PIKfyve-dependent phosphorylation of PI(3)P is
the only source for the production of PI(3,5)P2 in mammals
[14]. Next we asked whether expression of the intracellular
domain of APP, AICD, was also capable of stimulating the
formation of ML1Nx2 positive vesicles. AICD, when
released from APP by gamma-secretase cleavage, is a
soluble, cytosolic molecule that loses its membrane
attachment. We found that AICD-GFP expression strongly
stimulated the formation of ML1Nx2 positive vesicles,
mimicking the effect observed upon APP overexpression
(Fig. 2a, c). When testing the truncation mutants we found
that AICD-Tr.4 was able to stimulate the formation of
ML1Nx2 positive vesicles to a similar extent as full length
AICD (Fig. 2a, c), while AICD-Tr.2 and AICD-Tr.3 failed
to do so (Online Resource 1). It is interesting to note that
both AICD and AICD-Tr.4 are still able to stimulate for-
mation of ML1Nx2 positive vesicles, despite neither of
them being membrane attached by a transmembrane
domain. Binding of the PIKfyve complex (as established in
Fig. 1a–d) seems to be sufficient for the ability to provoke
an increase in ML1Nx2 positive vesicles.
In summary, in all AICD mutants characterised so far,
the ability to bind Vac14 perfectly correlated with their
ability to stimulate the formation of ML1Nx2 positive
vesicles upon overexpression. These data suggest that APP
requires Vac14 binding to stimulate PIKfyve-dependent
formation of ML1Nx2 positive vesicles.
To explore the nature of theML1Nx2 vesicles induced by
overexpression of APP we performed triple labelling using
APP-GFP, mCherry-ML1Nx2 and staining for EEA1 or
LampI. The large majority of APP/ML1Nx2 positive struc-
tures were also positive for EEA1, suggesting that these
vesicles are early endosomal in nature (Online Resource 2).
We also wanted to test whether APP or AICD overex-
pression has the same effect in a neuronal cell line. APP-
GFP or AICD-GFP were co-expressed together with
mCherry-ML1Nx2 in the SH-SY5Y neuroblastoma line
and compared to a GFP control (Online Resource 3). As in
HeLa cells both APP and AICD expression increased the
number of ML1Nx2 positive structures. Interestingly, in
SH-SY5Y cells APP seemed more effective than AICD at
increasing the number of ML1Nx2 vesicles.
These data show that in both neuronal and non-neuronal
cell lines overexpression of APP or AICD increased the
number of ML1Nx2 positive vesicles.
Suppression of APP and/or APLP2 compromises
PIKfyve-dependent processes
Are APP gene family members required for PIKfyve
activity? We tested this question using RNAi mediated
suppression of APP and the paralogue APLP2. Effective
suppression of APP, APLP2 or double suppression was
achieved with two different siRNA duplexes per gene
(Fig. 3a, b). Automated detection of ML1Nx2 positive
structures was used to test whether ML1Nx2 positive
vesicles are affected by APP gene family suppression. Both
single and double suppressions of APP and APLP2 led to a
reduction of the number of ML1Nx2 positive vesicles
(Fig. 3c). This showed that APP and APLP2 are required
for PI(3,5)P2 vesicle formation, not entirely surprising
given the high similarity of their intracellular domains and
their potential to interact with the PIKfyve complex.
It is well established that loss of PIKfyve activity
induced by expression of a kinase-dead version of PIKfyve,
RNAi suppression, mutation of PIKfyve complex genes or
pharmacological PIKfyve inhibition leads to a dramatic
and consistent accumulation of vacuoles in cells, aberrant
bFig. 1 Mapping of the interaction between APP’s intracellular
domain and the PIKfyve complex. a Sequences of the APP
intracellular domain AICD and truncations utilised. b Proteo-lipo-
somes displaying cysteine (negative control), AICD or truncations of
AICD. AICD and the N-terminal AICD-Tr.4 recruited PIKfyve and
Vac14 of the PIKfyve complex from pig brain cytosol while the
negative control and all C-terminal AICD truncations failed to do so.
c, d Quantification of Vac14 and PIKfyve bound to proteo-liposomes
displaying AICD and AICD truncation mutants (n C 3). Significant
differences (ANOVA test followed by Tukey’s post hoc analysis with
a = 0.05) are indicated. *p B 0.05, **p B 0.01, ***p B 0.001,
****p B 0.0001. Error bars are s.e.m. e Double-point mutations in
the highly conserved YENPTY motif and their impact on AICD’s
ability to interact with PIKfyve or Vac14. AICD mutations AANPTY
and YENPAA fully abolished its binding to Vac14 while YEAATY
strongly reduced the interaction. f, g Quantification of YENPTY
mutants and their interaction with Vac14 and PIKfyve (ANOVA test
followed by Tukey’s post hoc analysis with a = 0.05. *p B 0.05,
**p B 0.01, ***p B 0.001, ****p B 0.0001. Error bars are s.e.m.).
h AICD bound purified Vac14 in protein recruitments while the
negative control, cysteine did not. i Quantification of binding of
purified Vac14 to AICD proteo-liposomes. Analysed by Student’s
t test, *p B 0.05, n = 3. j MBP pull-downs showed that AICD and
AICD-Tr.4 interact with purified Vac14 while the MBP (negative
control) or AICD truncations 1–3 did not, confirming that AICD binds
Vac14 directly. k Protein sequence alignment of the intracellular
domains (ICD) of APP gene family members, highlighting the high
degree of homology of the intracellular domains. l APLP1 and, to a
lesser extent, APLP2 are both able to bind Vac14 and PIKfyve in
proteo-liposome recruitments compared to a cysteine control. m,
n Quantification of Vac14 and PIKfyve binding to APP, APLP1 and
APLP2 (ANOVA test followed by Dunett’s post hoc analysis with
a = 0.05. *p B 0.05, **p B 0.01, ***p B 0.001, ****p B 0.0001.
Error bars are s.e.m., n = 3)
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structures that were previously shown to be derived from
the endosomal system [16, 17, 20, 46]. We analysed
whether RNAi suppression of APP and/or APLP2 led to
such vacuoles. Suppression of APP and/or APLP2 led to an
increase of vacuole incidence compared to a control siRNA
(Fig. 3a). It is worthwhile noting that occurrence of
vacuolation is less pronounced with APP gene family
knock-down than with PIKfyve RNAi [16], suggesting that
APP family genes play an auxiliary rather than an essential
role in preventing vacuolation.
This idea would suggest that suppression of APP and
APLP2 will sensitise cells for PIKfyve inhibition. We
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tested this by inhibiting PIKfyve for a short period of time
(45 min). In control RNAi treated cells this brief PIKfyve
inhibition led to the formation of a number of small vac-
uoles. However, single suppression of APLP2 using RNAi
duplex I or double suppression of APP and APLP2 sig-
nificantly increased the incidence of vacuoles when
PIKfyve was briefly inhibited (Fig. 3d, e). APP or APLP2
RNAi duplex II had no significant effect on vacuolation.
These data show that double suppression of APP and
APLP2 sensitises cells for reduced PIKfyve activity,
leading to increased vacuolation. In this assay single sup-
pressions had no statistically significant effect (APP
duplexes) or variable effects in the case of APLP2.
APP requires PIKfyve activity for its trafficking
What is the purpose of APP binding to PIKfyve and
stimulating the formation of ML1Nx2 positive vesicles?
We noticed that upon PIKfyve inhibition using YM201636
a marked redistribution of APP-GFP occurred; instead of
localising to small vesicles throughout the cell, APP
became trapped in large, vacuolar structures (Fig. 2b). We
analysed APP-GFP localisation in more detail by inhibiting
PIKfyve using YM201636 and the recently established
Apilimod [47] in HeLa cells. APP-GFP accumulation in
vacuoles was dose dependent for both inhibitors with mild
effects observed with as little as 3 nM Apilimod (Online
Resource 4) and 100 nM YM201636 (Online Resource 5)
for 4 h. APP-GFP accumulation in vacuoles became pro-
gressively worse over a 4 h time course with both
inhibitors (1 lM YM201636 or 30 nM Apilimod) (Online
Resources 6 and 7). Next we analysed in what organelles
APP-GFP accumulated. We analysed the early endosomal
marker EEA1, late endosomal and lysosomal marker
LampI as well as the Golgi marker GM130. In control cells
APP could be detected in EEA1, LampI and GM130
compartments, consistent with its established trafficking
pattern [29, 48]. However, when PIKfyve was inhibited
using Apilimod we found a marked redistribution, with
APP accumulating in EEA1 positive structures and the
pools of APP in LampI positive late endosomes/lysosomes
and the Golgi apparatus diminished (Fig. 4a, b).
These data suggested that APP became trapped in early
endosomes or early endosome-derived vesicles upon PIK-
fyve inhibition with markedly reduced transport to both
late endosomes/lysosomes and the Golgi apparatus.
We also studied the protein levels of endogenous APP
and APLP2 to test whether they are affected by PIKfyve
inhibition. While APLP2 appeared largely unchanged, the
overall levels of APP increased strongly and its band pat-
tern in Western blot was altered (Fig. 4c, d). Particularly
the 135 kDa form strongly increased in quantity while the
approx. 110 kDa form remained largely unchanged. It has
previously been shown that human APP expressed from
cDNA results in a 135 and 110 kDa form, most likely
differing in their degree of glycosylation [49]. Taken
together these data show that APP trafficking and APP
levels depend on PIKfyve activity.
PIKfyve has two well-established roles in endosomal
function: Mediating endosome-to-TGN transport and
facilitating endosome/lysosome fusion [16, 19]. APP traf-
fics between the Golgi, plasma membrane and endosomes.
APP has previously been shown to undergo retromer-me-
diated endosome-to-TGN transport [31]. Our data show
that APP requires PIKfyve to avoid getting ‘stuck’ in early
endosomal-derived vacuoles which is fully compatible
with the important role that PIKfyve plays for the sorting of
receptors in endosomes [16].
Is PIKfyve function also required in neuronal cells for
APP trafficking? We tested this question by studying APP
trafficking in SH-SY5Y cells. As in HeLa cells, inhibition
of PIKfyve using Apilimod led to strong vacuolation and
APP-GFP trapping in vacuoles (Online Resource 8), sug-
gesting that PIKfyve is also required in neuronal cells for
APP trafficking.
It is conceivable that the endosomal population of APP,
by binding to and stimulating PIKfyve can drive local
production of PI(3,5)P2 and formation of carriers (as sug-
gested by the ML1Nx2 probe in Fig. 2) that may allow
APP sorting and escape from endosomes. If this is the case
we would expect a fraction of the APP label to co-localise
and co-migrate with ML1Nx2. We tested this by co-ex-
pressing APP-GFP and mCherry-ML1Nx2 and analysed
their behaviour in live cell imaging (Fig. 5a, b). APP-GFP,
bFig. 2 Overexpression of APP and AICD modulates PIKfyve
function. a, b Co-expression of GFP-tagged proteins and the
mCherry-labelled PI(3,5)P2 specific probe ML1Nx2 was used to
analyse the impact of APP-derived constructs on PI(3,5)P2 positive
structures in the absence (a) or presence of the PIKfyve inhibitor
YM201636 (b). Expression of APP, AICD or the N-terminal AICD
truncation mutant AICD-Tr.4 all increased the average number of
ML1Nx2 positive vesicles. In contrast, APP lacking its intracellular
domain (APPDAICD) and C-terminal AICD truncations (Tr. 2 and 3)
failed to increase the number of ML1Nx2 positive vesicles (Online
Resource 1). b The incidence of ML1Nx2 positive vesicles could be
nearly eliminated by PIKfyve inhibition (4 lM YM201636 for 4 h),
demonstrating that formation of ML1Nx2 positive vesicles is indeed
PIKfyve dependent. Bar 10 lm. c Automated quantification of the
number of mCherry-ML1Nx2 structures of 25 cells pooled from three
independent experiments for each condition were analysed (with 8–10
stacks acquired from each experiment) using image segmentation
(MosaicSuite in ImageJ [40]). Significant differences (ANOVA test
followed by Tukey’s post hoc analysis with a = 0.05) are indicated.
****p B 0.0001. Error bars are s.e.m.). d Quantification of average
ML1Nx2 intensity as analysed using MosaicSuite. APP, AICD and
AICD-Tr.4 expression did not majorly affect the average intensity of
mCherry-ML1Nx2 vesicles, suggesting that APP controls the number
of ML1Nx2 positive vesicles rather than the PI(3,5)P2 amount per
vesicle. Error bars are s.e.m.
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when expressed at low levels, displayed extensive co-lo-
calisation and co-migration with mCherry-ML1Nx2
(Online Resource 9), consistent with the idea that PI(3,5)P2
production is required for APP trafficking as suggested by
our PIKfyve inhibition experiments.
The analysis of the interaction interface between APP
and Vac14 highlighted the significance of the YENPTY
motif and the C-terminal, adjacent sequence (eliminated in
AICD-Tr.3). By consequence deletion of this sequence is
expected to disrupt PIKfyve-dependent APP sorting.
However, an important caveat is that the YENPTY motif
contains a classical NPxY endocytosis motif. Additionally
the C-terminal tyrosine of the YENPTY motif is part of the
YKFFE AP-4 binding motif required for APP exit from the
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Golgi [29]. We created the APP-Tr.3-GFP deletion con-
struct in which the FFEQMQN motif was deleted and
analysed its trafficking. Entirely consistent with work by
[29] APP-Tr.3-GFP accumulated in the Golgi (Online
Resource 10), virtually eliminating endosomal localisation,
precluding a closer analysis of PIKfyve-dependent, endo-
somal sorting.
Discussion
We have shown that the APP C-terminus binds the Vac14
subunit of the PIKfyve complex, an interaction necessary
for the formation of vesicles that are positive for the
TPRML-1 derived ML1Nx2 probe. The careful character-
isation of this probe by Li et al. suggests that the ML1Nx2
probe is indeed PI(3,5)P2 specific. For independent con-
firmation, we used PIKfyve inhibition and studied the
impact on the ML1Nx2 probe. PIKfyve inhibition nearly
completely eliminated vesicular localisation of ML1Nx2,
also suggesting that ML1Nx2 is a bona-fide PIKfyve
function reporter.
To our knowledge, this is the first mammalian Vac14
binding partner established outside the PIKfyve complex
that has been shown to modify PIKfyve function. Previ-
ously it was shown that PIKfyve could interact with Rab9
effector p40 and the kinesin adaptor JLP [50, 51].
We found that both APP and AICD overexpression were
able to stimulate formation of PI(3,5)P2 positive vesicles,
suggesting that APP is able to modulate or direct PIKfyve
activity. It could be speculated that APP, as a transmem-
brane protein may provide membrane attachment for the
PIKfyve complex. In that case, AICD should act as a
competitive inhibitor for PIKfyve complex membrane
attachment. AICD overexpression should lead to dissocia-
tion of PIKfyve from the membrane and reduce PIKfyve’s
ability to form PI(3,5)P2. However, we observed that AICD
overexpression increased the number of PI(3,5)P2 positive
vesicles to the same extent as APP overexpression in HeLa
cells, and to a slightly lower extent in SH-SY5Y cells. It is
also worthwhile noting that PIKfyve possesses the PI(3)P
binding FYVE domain which is well established to allow
membrane association with endosomes [52]. Both facts
argue against a role for APP in providing membrane
attachment for the PIKfyve complex and rather argue for a
role in modulating its activity.
We have shown that APP and APLP2 knock-down
reduced the number of PI(3,5)P2 positive vesicles and
increases the susceptibility of cells to form vacuoles,
particularly when PIKfyve function is compromised. We
have also shown that APP trafficking is dependent on
PIKfyve activity in both HeLa and SH-SY5Y cells. From
these data we propose a working model in which APP,
upon arrival in the early endosome, interacts with the
PIKfyve complex by binding Vac14 and triggers the
formation of PI(3,5)P2 positive vesicles. This allows APP
(and potentially other cargoes) to be sorted away from the
endosomal system. Pharmacological inhibition of PIKfyve
activity suppressed this interplay and led to the trapping
of APP in early endosomal, aberrant, vacuolar structures
(Fig. 6).
This study revealed an interesting reciprocal relationship
between APP and the PIKfyve complex in which APP can
bind to the PIKfyve complex, stimulate formation of
PI(3,5)P2 positive vesicles and in turn regulate its own
trafficking. Thus, we have established a novel role for
members of the APP gene family as regulators of endo-
somal phosphoinositide metabolism. This function is
certainly shared by APP and APLP2. Whether this is
equally true for the brain-specific APLP1 remains to be
tested; however, as all three can bind Vac14 of the PIKfyve
complex this is likely.
From our data it is clear that the intracellular domain of
APP is crucial for its interplay with PIKfyve. Most likely it
modulates PIKfyve function by direct binding to the Vac14
subunit of the complex. Vac14 is known to act as a scaffold
that brings PIKfyve and Fig4 together [13]. However, how
exactly binding of APP to Vac14 may translate into altered
PIKfyve activity is unclear in the absence of any structural
information. It is possible that APP binds PIKfyve or Fig4
in addition to Vac14. So far we have not been able to
express and purify Fig4 or PIKfyve, so we have not been
able to test this directly. However, one argument weighs
against the idea of an additional binding site for another
PIKfyve complex member in the APP intracellular domain:
bFig. 3 APP and APLP-2 suppression disrupts PIKfyve-dependent
processes. a siRNA duplex sequences utilised and percent of HeLa
cells in which vacuoles were observed after suppression of APP,
APLP2 or double suppression. Incidence of vacuoles was increased
upon single or joint suppression of both APP and APLP2. b Confir-
mation of successful knock-down of APP and APLP2 by western
blotting. c Joint suppression of APP and APLP2 by RNAi and
automated detection of ML1Nx2 positive vesicles. Single or joint
suppression of APP or APLP2 resulted in a significant reduction of
ML1Nx2 positive structures compared to the Luciferase negative
control duplex (ANOVA test followed by Tukey’s post hoc analysis,
n = 3). d, e RNAi suppression of APP and APLP2 combined with
limited PIKfyve inhibition (1 lM, 45 min) and quantification of the
number of apparent number of vacuoles. Under these conditions only
few, small vacuoles (arrows) were detected in the Luciferase control,
while suppression of APLP2 using duplex I and double suppression of
both APP and APLP2 significantly increases vacuole number
(quantified in e), suggesting that joint suppression of APP and
APLP2 sensitises HeLa cells for PIKfyve inhibition. c, e Statistical
test using ANOVA followed by Tukey’s post hoc analysis. a = 0.05,
only significant differences are indicated, *p B 0.05, **p B 0.01,
***p B 0.001, ****p B 0.0001. Number of cells analysed per
condition are indicated in each bar in the diagram. Error bars are
s.e.m., n = 3)
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In all interaction experiments in which we studied various
AICD mutants (deletion or ‘double point’), binding of
PIKfyve to AICD behaved exactly as binding to Vac14,
e.g., any mutation abolishing binding to Vac14 also
abolished the binding to PIKfyve. This observation does
not easily fit with the possibility of an additional binding
site in the APP intracellular domain for PIKfyve. However,
we cannot currently exclude the possibility.
Fig. 4 Inhibition of PIKfyve disrupts endosomal sorting of APP.
a APP-GFP localisation in the absence or presence of the PIKfyve
inhibitor Apilimod (100 nM, 4 h), co-labelled with early endosomal
marker EEA1, late endosomal/lysosomal marker LampI and Golgi
marker GM130. Upon PIKfyve inhibition, APP accumulated in EEA1
positive vacuoles, while little overlap with LampI was detected.
PIKfyve inhibition also reduced APP label detectable in the Golgi
area. b Quantification of APP-GFP label in EEA1, LampI and GM130
structures. EEA1, LampI or GM130 staining was used to define a
mask and the percentage of cellular APP label contained inside the
mask was measured in three independent experiments and expressed
as a percentage of total APP-GFP label. PIKfyve inhibition led to a
marked increase of APP in EEA1 positive structures, while APP label
in LampI and GM130 positive structures was significantly decreased
as tested using unpaired Student’s t test (**p\ 0.01, ***p\ 0.001,
error bars are s.e.m.). Total number of cells analysed per condition is
indicated in each bar in the diagram. Between 10 and 12 stacks were
collected from three independent experiments and pooled. c APP
accumulated in cells upon overnight inhibition of PIKfyve using
4 lM YM201636 as analysed by western blotting. The total of all
APP species was increased approximately fivefold (n = 6). Particu-
larly the 135 kDa form was affected by PIKfyve inhibition. d No
major change was detected for APLP2
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Another open question is how PIKfyve function enables
endosomal sorting. While it is clear that the enzyme plays a
pivotal role for endosome-to-TGN transport, the mecha-
nism thereof remains unclear [16]. Answering this question
will be challenging as our knowledge of PI(3,5)P2 effectors
that may contribute to endosomal sorting is extremely
limited. However, combining the ML1Nx2 probe and APP
as a prospective cargo may provide valuable insights into
the formation of PI(3,5)P2 vesicles and how PIKfyve
function underpins endosomal receptor sorting.
Fig. 5 APP co-localises and
co-migrates with the PI(3,5)P2
marker ML1Nx2. a Live cell
imaging of APP-GFP and
mCherry-ML1Nx2 evidenced
colocalisation of both on
multiple vesicles throughout the
cell (examples are indicated by
arrows in enlargements).
b Co-labelling of APP-GFP and
mCherry-ML1Nx2 positive
vesicles showed that both reside
on vesicles that track through
the cell (examples are indicated
by arrows). Bars 20 lm
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Implications of the APP/PIKfyve interplay
for Alzheimer’s disease
Conclusive genetic as well as biochemical evidence has
demonstrated that APP cleavage by beta- and gamma-
secretase, producing beta-amyloid on the one hand and
destroying APP on the other is a key event in Alzheimer’s
disease. Our work has shown that APP biochemically and
functionally interacts with the PIKfyve complex. Previous
work from the Weisman and Meisler labs has clearly
demonstrated that the PIKfyve complex is central to neu-
ronal function and integrity. Compromised PIKfyve
function by knock-out or reduced activity of the PIKfyve
complex led in all cases to endosomal dysfunction coupled
with dramatic neurodegeneration as evidenced in mice and
humans [14, 17, 21, 22]. All of the data presented here
suggest that APP family members act as PIKfyve activators
to support PIKfyve function. This is supported by our
recent study in which we showed that the C. elegans
homologue of APP, APL-1 is genetically linked to PIKfyve
and is required for PIKfyve function in the nematode
(Balklava et al., in press). This interplay is likely to be
perturbed by aberrant APP processing as observed in
Alzheimer’s disease. Excessive cleavage of APP is likely
to reduce its ability to interact with and stimulate PIKfyve
function, thereby compromising endosomal sorting and
homeostasis. Disrupted endosomal function (including
autophagy) is well established to occur early during Alz-
heimer’s disease and is thought to contribute to
neurodegeneration [53]. By consequence, a perturbed APP/
PIKfyve interplay could represent an entirely novel
mechanism by which APP cleavage may cause
neurodegeneration.
This idea highlights a number of open questions: (1)
How does a compromised endo/lysosomal system as
caused by loss of PIKfyve function lead to neurodegener-
ation? (2) Can evidence for PIKfyve dysfunction be
obtained in Alzheimer’s disease models or patient sam-
ples? (3) Could pharmacological, ectopic activation of
PIKfyve reduce/eliminate endosomal dysfunction and
prevent neurodegeneration? If so, this would provide an
alternative to the largely failed quest for preventing beta-
amyloid production or deposition as treatment in Alzhei-
mer’s disease. Answering these questions may provide a
completely novel view of the causes of neurodegeneration
in Alzheimer’s disease.
Acknowledgments We would like to thank Dr. Weisman and Dr.
Xu (University of Michigan) for kindly providing plasmids for
expression of Vac14 and ML1Nx2, respectively. We thank the
ARCHA microscopy facility (Aston University) for access to wide-
field and confocal microscopy. We acknowledge funding from the
Biotechnology and Biomedical Sciences Research Council (BB/
K014862/1) and Alzheimer’s Research UK (ARUK-PhD2012-13).
We thank Sehar Sajid (Aston University) for technical assistance.
Compliance with ethical standards
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
Fig. 6 Working model of the APP/PIKfyve interplay. Our data
suggest that APP, upon delivery to early endosomes can bind to and
stimulate PIKfyve to produce PI(3,5)P2 positive vesicles. This may
allow APP sorting and escape from endosomes. PIKfyve is necessary
for APP sorting from endosomes, as pharmacological inhibition
demonstrated that APP remains ‘stuck’ in endosome-derived vac-
uoles. Our data also suggest that PIKfyve function is required for APP
trafficking to LampI positive late endosomes and lysosomes and
potentially APP downregulation
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